Wells Fargo Maintains Equal-Weight on DocuSign, Raises Price Target to $65
Wells Fargo analyst Michael Turrin maintains DocuSign (NASDAQ:DOCU) with a Equal-Weight and raises the price target from $55 to $65.
10 Information Technology Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Why This DocuSign Analyst Has Just Turned Bearish
Shares of DocuSign Inc (NASDAQ: DOCU) came under pressure last week, after the company announced plans to slash 10% of its workforce.
FTX’s Bankruptcy: A Who’s Who of Institutional Creditors
As the bankruptcy proceedings for failed cryptocurrency exchange FTX continue, a court filing on Wednesday finally lifted the veil on the long-awaited list of institutional creditors.
The document, spanning over 100 pages, delves into the depths of the companies and entities caught up in the web of FTX's downfall.
Insiders Selling DocuSign, Adobe And 2 Other Stocks
The Nasdaq settled higher by 2% on Monday. Investors, meanwhile, focused on some notable insider trades.
Expert Ratings for DocuSign
Analysts have provided the following ratings for DocuSign (NASDAQ:DOCU) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Vail Resorts, DocuSign And This Leading Homebuilding Stock Trading 9 Times Earnings On CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said Vail Resorts, Inc. (NYSE: MTN) is a company with a high debt load.
Looking At DocuSign’s Recent Unusual Options Activity
Someone with a lot of money to spend has taken a bullish stance on DocuSign (NASDAQ:DOCU).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Citigroup Maintains Buy on DocuSign, Raises Price Target to $72
Citigroup analyst Tyler Radke maintains DocuSign (NASDAQ:DOCU) with a Buy and raises the price target from $59 to $72.
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday’s Mid-Day Session
Gainers
Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.